Trial Profile
A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy in Hematological Centers in Belgium Using Gene Expressing Profiling From Baseline Bone Marrow.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Myelodysplastic syndromes
- Focus Pharmacodynamics
- Acronyms EXPHAR
- Sponsors Novartis
- 20 Jul 2017 Status changed from recruiting to discontinued.
- 08 Feb 2017 This trial has been Discontinued in Belgium according to European Clinical Trials Database record.
- 21 Sep 2016 Planned End Date changed from 1 Apr 2017 to 1 Nov 2017.